Figure 11. This figure compares the PFS in patients with advanced metastatic PNENs, (A) treated with Sunitinib in the SUN 1111 trial (194) and (B) Everolimus in the RADIANT 3 trial (198). Figure A was retrieved and adapted from The New England journal of medicine, Raymond E., Dahan L., Raoul J. L., et al., Sunitinib malate for the treatment of pancreatic neuroendocrine tumors, 364 (6): 501-13 © 2011 (194). Figure B was retrieved and adapted from The New England journal of medicine, Yao J. C., Shah M. H., Ito T., et al., Everolimus for advanced pancreatic neuroendocrine tumors, 364 (6): 514-23 © 2012 (198).